Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study

Description

Zareen Kiran and five colleagues compared two diabetes drugs for safety during Ramadan fasting at a single center. Fasting from dawn to dusk destabilizes blood sugar, and sulfonylurea drugs are notorious for causing dangerous lows. The prospective cohort ran from March to June twenty twenty-two. Patients on stable empagliflozin or sulfonylurea regimens, alongside other standard drugs, were followed through the fast. Hospital admissions for hypoglycemia and blood sugar control were the outcomes.

The empagliflozin group reported slightly fewer hypoglycemic episodes, about twenty-seven versus thirty-one percent. Both groups improved their long-term glucose marker significantly and similarly. Women made up sixty percent of the empagliflozin group. For the hundreds of millions who fast with diabetes, even small safety margins matter. This twenty twenty-five study supports preferring the newer drug class when lows are the chief fear.

Catalog record

Source: https://europepmc.org/articles/PMC12849180